Title | Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | M Calvo-Vidal N, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J, Yang SNing, Yang L, Taldone T, Thieblemont C, Leonard JP, Martin P, Inghirami G, Chiosis G, Manalis SR, Cerchietti L |
Journal | Cancer Res |
Volume | 81 |
Issue | 20 |
Pagination | 5202-5216 |
Date Published | 2021 10 15 |
ISSN | 1538-7445 |
Keywords | Animals, Carcinogenesis, Case-Control Studies, HSP90 Heat-Shock Proteins, Humans, Lymphoma, Large B-Cell, Diffuse, Metabolome, Mice, Protein Interaction Domains and Motifs, Proteolysis, Proto-Oncogene Proteins c-myc, Signal Transduction, Tumor Cells, Cultured |
Abstract | HSP90 is critical for maintenance of the cellular proteostasis. In cancer cells, HSP90 also becomes a nucleating site for the stabilization of multiprotein complexes including signaling pathways and transcription complexes. Here we described the role of this HSP90 form, referred to as oncogenic HSP90, in the regulation of cytosolic metabolic pathways in proliferating B-cell lymphoma cells. Oncogenic HSP90 assisted in the organization of metabolic enzymes into non-membrane-bound functional compartments. Under experimental conditions that conserved cellular proteostasis, oncogenic HSP90 coordinated and sustained multiple metabolic pathways required for energy production and maintenance of cellular biomass as well as for secretion of extracellular metabolites. Conversely, inhibition of oncogenic HSP90, in absence of apparent client protein degradation, decreased the efficiency of MYC-driven metabolic reprogramming. This study reveals that oncogenic HSP90 supports metabolism in B-cell lymphoma cells and patients with diffuse large B-cell lymphoma, providing a novel mechanism of activity for HSP90 inhibitors. SIGNIFICANCE: The oncogenic form of HSP90 organizes and maintains functional multienzymatic metabolic hubs in cancer cells, suggesting the potential of repurposing oncogenic HSP90 selective inhibitors to disrupt metabolism in lymphoma cells. |
DOI | 10.1158/0008-5472.CAN-21-2734 |
Alternate Journal | Cancer Res |
PubMed ID | 34479963 |
PubMed Central ID | PMC8530929 |
Grant List | R01 AG067598 / AG / NIA NIH HHS / United States R01 CA242069 / CA / NCI NIH HHS / United States |